Breo(SH:688793) Shang Hai Zheng Quan Bao·2025-08-21 19:00Group 1 - The company plans not to distribute profits for the first half of 2025, including no cash dividends or stock bonuses, to ensure sustainable development and protect long-term shareholder interests [4] - The board of directors confirmed the authenticity, accuracy, and completeness of the half-year report, which has not been audited [3][6] - The company reported an unallocated profit of -41,204,869.29 yuan as of June 30, 2025, indicating that the unallocated losses exceed one-third of the paid-in capital [17] Group 2 - The company has faced challenges due to macroeconomic fluctuations, structural changes in consumer behavior, and intensified industry competition, leading to cautious spending among high-income consumers [18] - The company is implementing strategic adjustments focused on "technology empowering health," leveraging its strengths in traditional Chinese medicine and technology to enhance brand loyalty and consumer experience [19] - The company is pursuing a global strategy to expand into emerging markets and key channels, aiming to build a diverse and robust international business system [19] Group 3 - The company raised 422.23 million yuan through its initial public offering, with a net amount of 358.91 million yuan after deducting fees [22][23] - As of the reporting period, the company had a remaining balance of 57.54 million yuan in raised funds, primarily due to ongoing projects [23][27] - The company has established a management system for raised funds, ensuring compliance with relevant laws and regulations [25][26]